Security key
74365A309
Protalix BioTherapeutics, Inc. - Common Shares (PLX)
CUSIP: 74365A309
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Shares
- Total 13F shares
- 3,383,529
- Total 13F value
- $3,451,053
- Share change
- -2,087,873
- Put/Call ratio
- 59%
- SEC-reported price per share
- $1.02
- Number of holders
- 43
- Value change
- -$2,253,845
- Number of buys
- 10
- Number of sells
- 46
- Shares outstanding
- 79,957,519
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
43
Top holders
10
PLX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74365A309
Recent filing periods:
Ownership snapshot
Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
23 Sep 2024
3/4/5
13F
Highest disclosed value: $5,128,613
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $5.13M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value
Top 5
Dexcel Pharma Technologies Ltd.
$5.13M
MILLENNIUM MANAGEMENT LLC
$949.1K
RENAISSANCE TECHNOLOGIES LLC
$941.4K
Eyal Rubin
$931.9K
GOLDMAN SACHS GROUP INC
$540.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$5,128,613
3,637,314 shares
|
— | 02 Jun 2021 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$949,057
811,160 shares
|
— | 30 Jun 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$941,382
804,600 shares
|
— | 30 Jun 2024 |
| Eyal Rubin |
3/4/5
Sr. VP and CFO
|
—
denominator unverified
|
$931,882
660,909 shares
|
— | 23 Sep 2024 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
—
denominator unverified
|
$540,491
461,958 shares
|
— | 30 Jun 2024 |
| NORTHERN TRUST CORP |
13F
Company
|
—
denominator unverified
|
$495,159
423,213 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
43
Shares
3,383,529
Rows available
43
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
64
Q3 2024 holders
43
Holder diff
-21
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend